PDX model details
| PDX ID | 167.2M Cx |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Castrate |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
29 (12*) |
| Average PDX Generation Time (days +/- SEM) | 94 ± 7 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304; 33620092 |
| Markers | 167.2M Cx |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 167.2M Cx | AKT3 | 0.521 | 2.871 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | XPO1 | 0.511 | 2.851 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | SPEN | 0.554 | 2.936 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | PIK3CB | 0.781 | 3.437 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | PIK3CA | 0.781 | 3.437 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | IGF2R | 0.560 | 2.948 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | CCND1 | 1.105 | 4.302 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | ARID2 | 0.594 | 3.018 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | STAB2 | 0.584 | 2.999 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | NCOR2 | 0.606 | 3.043 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | FOXA1 | 1.163 | 4.478 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | AR | 2.950 | 7.730 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | PTEN | -10.674 | 0.001 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | APC | -1.511 | 0.702 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 167.2M Cx | ZNRF3 | -1.477 | 0.718 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 167.2M |
|---|---|
| Sample Site | Spine |
| Sample source | Surgery |
| Pathology Tumour Diagnosis | Adenocarcinoma |
| Gleason Score | 9 |
| Primary Gleason Score | 4 |
| Secondary Gleason Score | 5 |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel |
Patient Information
| Patient Number | 167 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 5.2 |
| Consent to share data | |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 167.2M |
| Patient Age (binned in 5 year age groups) | 55-59 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 167.2M Cx | TP53 | 211 | 1.0 | Missense variant | '7/11 | . | 32 | Uncertain significance | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 167.2M Cx | APC | 85 | 0.88 | Frameshift variant | '16/16 | . | 34 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 167.2M Cx | PRLR | 532 | 0.54 | Missense variant | '10/10 | 0.0008899 | 23.2 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 167.2M Cx | DCLK3 | 372 | 0.41 | Missense variant | '4/5 | . | 25.3 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
This table displays drug response data
qd->once daily; qwk->once weekly The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
qd->once daily; qwk->once weekly The table can be sorted by any field. However, please note that when you click on a column header to sort, there might be a brief delay
| PDX ID | Treatment1 | Dose (mg/kg) | Frequency | Treatment2 | Dose (mg/kg) | Frequency | Response |
|---|---|---|---|---|---|---|---|
| 167.2M Cx | Carboplatin | 50 | qwk | NA | NA | NA | Response |
| 167.2M Cx | Talazoparib | 0.33 | qd | Carboplatin | 50 | qwk | No response |
| 167.2M Cx | Talazoparib | 0.33 | qd | NA | NA | NA | No response |